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Objective: To examine the efficiency of a 1000 cc intragastric balloon as an aid for weight
reduction.
Subjects: Thirty-three morbidly obese persons, after multiple attempts for weight loss.
Design: Intragastric 1000cc balloons were endoscopically inserted into the stomachs of
subjects. The balloons were left in place for six months. During that period the patients
received dietary therapy. Hormone levels were measured prior to insertion and upon with-
drawal of balloons.
Results: After a brief initial weight loss, most patients regained the weight initially
lost. Mean weight loss after six months was only 8 kg (range 0-22 kg). We found that
Bombesin levels, but not Gastrin levels, were significantly lower at the end of therapy than
before insertion of the balloon.
Conclusion: We conclude that a large intragastric balloon for a prolonged time did not
assist in weight loss. Our preliminary results show Bombesin levels change significantly, a
finding which warrants further study.
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INTRODUCTION
Use of intragastric balloons as part of the therapeu-
tic intervention program for weight reduction is an
attractive theoretical approach that has met with
technical difficulties. This caused most physicians
to currently forego this option in treating obesity
[1]. Over the past decade, several types of intragas-
tric balloons were tested and not found to be defi-
nitely better than other nonsurgical approaches
[2,3]. The Garren-Edwards balloon, a 200 cc bub-
ble, was found to be associated with serious compli-
cations [4]. The 500cc Danish Balloobes Bubble
was found to be safe but not more effective than a
very low calorie diet with medical and dietary sup-
port [5,6]. The purpose of the present study was to
test the hypotheses that a larger volume balloon
and/or a longer duration of insertion would be
more effective than those previously used, without
compromising patient safety. An additional objec-
tive of this research was to study the effect of gastric
distension on serum Bombesin and Gastrin levels.
Corresponding author.32 A. LAVY et al.
METHODS
Thirty-three morbidly obese patients were
admitted to an open trial. Criteria for inclusion in
the study were severe obesity, failure at maintain-
ing weight loss from previously attempted non-
invasive approaches, and fully informed consent
as required by the Helsinki Committee. Severe
obesity was defined using the National Health
and Nutrition Examination Survey (NHANESII)
criteria [7]. Exclusion criteria were the presence
of severe systemic disease, prior gastric surgery,
peptic ulcer disease, primary endocrine disorders,
coagulation disturbances, age under 18 years, and
pregnancy. The patients included nine men, mean
age 39 years (range 18-46 years), and 24 women,
mean age 36 years (range 21-66). The mean
weight for men was 108.7 kg (range 100-140 kg);
for women mean weight was 108.4kg (range
95-140 kg).
Blood count, coagulation evaluation, and serum
electrolytes were examined prior to insertion, and
following removal of the balloon.
Dietary Assessment
Every patient was closely followed with twice-
monthly meetings with a dietician, and weekly
physician follow-up, but did not receive behavioral
modification therapy. The dietician took extensive
dietary histories, created a personalized diet plan
for every patient, allowing for 1000-1200 calories
daily, and including a multivitamin supplement.
Follow-up dietician visits focused on allowable
substitutions within the caloric framework, and
reinforcement.
outpatient basis. Following esophagogastroduo-
denoscopy the balloon was inserted alongside the
endoscope, using a snare device to hold the bal-
loon in place. After inflation of 1000 cc of air, the
inflation catheter and endoscope were removed.
Removal of balloons was performed by punctur-
ing the balloon with a sclerotherapy needle, and,
after deflation, snare removal. Volume stability
and positioning was followed by plain film X-rays
of the abdomen (see Fig. 1).
Hormonal Measurements
There are several reports which have explored
the associations and putative roles of peptide
hormones and satiety [8]. The best studied are
Cholecystokinin, Pancreatic Glucagon and Bom-
besin. Gastric dilatation causes gastric secretion in
the rat, through activation of Bombesin neurons
[9]. In the human, variable effects have been
reported [10-12]. The influence of Bombesin on
Gastrin release has been demonstrated in various
situations [13]. We attempted to determine
whether chronic gastric distension as caused by a
Balloon Qualities
The balloon used was produced by the Tremco
Company (Nethanya, Israel) from a mixture of
synthetic thermostatic elastomeres, enabling the
1000 cc volume expansion without loss of stability.
It had a smooth surface with radio-opaque surface
markers. The procedure was performed on an FIGURE 1000 cc air-filled balloon in the stomach.1000cc INTRAGASTRIC BALLOON, BOMBESIN, GASTRIN 33
balloon, would have any effect on Gastrin and/or
Bombesin. Serum Bombesin and Gastrin levels
were measured prior to insertion of the balloon,
and six months after insertion of the balloon,
before its withdrawal. Gastrin was measured by
radioimmunoassay (CIS bioindustries GASK-PR
kit, France). Bombesin was measured by radio-
assay using INCSTAR Bombesin 125/RIA kit
MN, USA.
RESULTS
Following insertion of the balloon, most patients
experienced nausea, cramps, and vomiting lasting
3-5 days and all patients lost weight during the
first three weeks. Over the next six months, only
one patient complained of abdominal pain, occur-
ring three months after insertion of the balloon.
Endoscopy was performed and revealed a hallow
gastric ulcer. The balloon was removed and the
patient recovered. No other patient had notable
side effects. There were no extraction difficulties
in removing the balloons.
After the short-lived initial weight loss most
patients ceased to lose weight and then proceeded
to regain the weight initially -lost (see Table I and
Fig. 2). Mean weight lost after six months was
6 kg (range 0-22 kg). A frequent sensation experi-
enced by patients was abdominal discomfort
relieved by eating, and it was thus difficult for
them to skip or reduce the size of meals.
The results of the peptide hormonal studies
were as follows: prior to insertion of the balloon
Gastrin level (pg/ml) was 46.3 SD 2.8. After
six months, prior to withdrawal, the Gastrin
level was 41.2 SD 2.2. This difference showed a
nonsignificant trend towards decreased gastrin
distension. Bombesin level prior to insertion was
39.4 SD 5.9pg/ml, and six months later, before
balloon withdrawal was 16.9 SD 3.4 pg/ml. This
difference was statistically significant, p < 0.001
(see Table II).
We found no correlation between Bombesin
level and the weight of the patients.
Table of sex, age and weight of patients
Age Weight (in kg)
Initial At 2 weeks At 6 months Change
TABLE
Females
37 110 100 110 0
44 95 87 96
41 109 101 109 0
36 100 94 100 0
46 115 107 103 12
21 130 122 118 12
32 95 79 95 0
33 133 129 133 0
30 100 96 100 0
28 130 122 121 9
30 96 93 74 22
30 97 90 91 6
38 105 101 105 0
66 133 127 128 5
45 96 90 84 12
45 100 95 87 13
44 111 109 111 0
21 120 120 120 0
21 130 130 130 0
29 106 100 106 0
32 101 96 84 17
43 98 92 88 10
37 95 89 85 10
29 97 93 97 0
Average
36 108.4 102.6 103.1
Males
46 109 103 109 0
45 102 97 88 14
39 108 102 103 5
40 100 92 81 19
42 113 106 98 15
18 105 98 85 2O
44 100 9O 100 0
45 102 96 103 -1
37 140 138 140 0
Average
39 108.7 102.4 100.7
110
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TABLE II Mean Gastrin and Bombesin serum levels before
and six months after balloon insertion
Gastrin (pg/ml) Bombesin (pg/ml)
Prior to insertion 46.3 (SE 2.8) 39.4 (SE 5.9)
10min after insertion 48.6 (SE 2.8)
Prior to withdrawal 41.2 (SE 2.2) 16.9 (SE 3.4)*
10 min after removal 41.4 (SE 1.9)
SE Standard error.
*p < 0.001 (Student’s t-test).
DISCUSSION
Mathus-Vliegen and Tytgat [5] in 1990 asked the
question: "Would a higher-volume and longer-
lasting balloon promote a greater weight loss or
prolong adherence and compliance to treatment?"
The present study was designed specifically to
answer this important question. The balloon was
designed to allow for a 1000cc volume and was
left in place for six months, as compared to
recommended usage of the Garren-Edwards bal-
loon, using 200cc for 12 weeks. The balloon was
unique in being air-filled rather than fluid-filled.
Because our focus was to examine the result of a
high volume balloon, we chose to use a constant
volume of air, rather then adjust volume to the
patient, as had been suggested at the Tarpon
Springs Comprehensive Workshop [4]. Our bal-
loon did not produce significant long-term weight
loss. Our patients came to twice-monthly dietician
and weekly physician interviews, but continued
to experience hunger and discomfort which was
relieved by eating. We could not establish whether
this discomfort and cramping were the result of
the balloon, a possible side effect, or from hunger
related to the eating habits of the patients.
Patients indicated that their hunger returned to
the level it had been at before the balloon inser-
tion, only 2-3 weeks after the balloon was
inserted. Dietary assessments by physicians and
dieticians, including use of substitutions and
considerable encouragement and support, aiming
for 1000-1200kcal/day diets, left us with the
impression that patients eating habits were un-
affected by the balloon after the initial period of
adaptation to its effect.
We found the level of Bombesin but not of
Gastrin to be significantly reduced after the six
months of gastric distension by the balloon.
Short-term studies of gastric dilatation have
shown that the level of distension is correlated
with changes in Gastrin levels in the rat. Perhaps
because of a lack of impressive weight loss by the
end of the six month duration of the study, our
data did not establish a significant relationship
between the level of weight loss and the level of
change of Gastrin or Bombesin when matched per
individual, but the mean level of Bombesin for the
group was significantly reduced. Why did Bombe-
sin levels drop significantly in patients who had
adapted to an intragastric balloon? Bombesin has
been described as the hormone most likely to be
responsible for satiety. Unlike Gastrin and Soma-
tostatin, Bombesin retains its satiety effect even
after complete denervation of the stomach [14].
We speculate that perhaps adaptive mechanisms
led to overriding of a satiety effect of reduced
Bombesin.
In the National Institutes of Health Consensus
Development Conference Statement, specific
needs were identified in the research for more
effective alternate forms of weight reduction
therapy [15]. Until the physiology of morbid
obesity is better understood and appropriate inter-
ventions developed, our efforts may best be direc-
ted towards elucidating the pathophysiology of
obesity, and meanwhile towards behavior modi-
fication and other noninvasive and invasive
approaches. One survey of 50 experts significantly
viewed the potential for anorectic drugs in the
next ten years as considerably better than at
present [16].
Our patients did not experience weight loss for
a significant duration. These patients were self
selected; they were highly motivated, severely
obese patients who had all failed in many previous
attempts to lose weight by other means.1000cc INTRAGASTRIC BALLOON, BOMBESIN, GASTRIN 35
CONCLUSIONS
We conclude that neither intragastric balloon size
nor the duration of use of the balloon could be
demonstrated to be critical factors in determining
the effectiveness of a weight loss program utilizing
this modality. The reduction in the serum level of
Bombesin, but not of serum Gastrin, following six
months of balloon distension suggest that these
hormones may be involved in a new homeostasis
which may prevent feeling satiety despite having a
small available gastric volume. This may be the
cause for failure of various trials aimed at redu-
cing intake by causing early satiety.
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